MIL95 / Beijing Mabworks Biotech, Keymed Biosciences  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MIL95 / Beijing Mabworks Biotech, Keymed Biosciences
ChiCTR2100042046: MIL95-CT101

Recruiting
1
58
 
MIL95
Beijing Cancer Hospital; Beijing Mabworks Biotech Co., Ltd., self-finance
lymphomas and advanced malignant solid tumors
 
 
NCT04651348: A Clinical Study of MIL95 in Advanced Malignancies.

Recruiting
1
58
RoW
Recombinant Humanized Monoclonal Antibody MIL95
Beijing Mabworks Biotech Co., Ltd.
Advanced Malignancies
12/22
11/24

Download Options